Stock Groups

Novo Nordisk shares slump on U.S. supply challenges for obesity drug -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO A Novo Nordisk logo coffee machine is seen in Copenhagen (Denmark) on February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo

COPENHAGEN, Reuters – Novo Nordisk’s (NYSE:), shares dropped 16% Monday following a late Friday announcement by the Danish drugmaker that it would not be able meet the demand for the new weight loss drug. This was due to supply problems in the United States.

In a stock release, the Danish drugmaker stated that after problems with manufacturing practices and deliveries of Wegovy drugs to contract manufacturers, a manufacturer who was filling syringes with pens for its Wegovy drug temporarily stopped production.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from relying on data including charts, buy/sell signals, and quotes. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]